TCM
RCKT icon

Tuttle Capital Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Tuttle Capital Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,027
Closed -$267K – 236
2021
Q2 		$267K Buy
+6,027
New +$262K 0.12% 205

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Tuttle Capital Management's RCKT Position: Q3 2021 in Review

Tuttle Capital Management sold out of Rocket Pharmaceuticals (RCKT) in Q3 2021, closing a stake of 6,027 shares — an estimated $267K sold.

Tuttle Capital Management first reported a position in RCKT in Q2 2021 and held it in 1 quarter. The position peaked at $267K in Q2 2021. 146 funds tracked by Wall St. Rank hold RCKT as of Q3 2021.

  • Tuttle Capital Management reported no remaining Rocket Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Tuttle Capital Management sold 6,027 Rocket Pharmaceuticals shares in Q3 2021, an estimated $267K.
  • Tuttle Capital Management first reported a position in Rocket Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Tuttle Capital Management's Rocket Pharmaceuticals position peaked at $267K in Q2 2021.
  • 146 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2021.

Based on Tuttle Capital Management's 13F filing for Q3 2021, filed 20 Oct 2021.